Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences

OBJECTIVE: Enzyme replacement therapy (ERT), the only approved therapy for infantile-onset Pompe disease (IOPD), had heterogeneous clinical effects due to factors such as severity, age at first treatment, dosage, and dosing regimens. We report the clinical and biochemical outcomes of a cohort of IOP...

Descripción completa

Detalles Bibliográficos
Autores principales: Chien, Yin-Hsiu, Tsai, Wen-Hui, Chang, Chaw-Liang, Chiu, Pao-Chin, Chou, Yen-Yin, Tsai, Fuu-Jen, Wong, Siew-Lee, Lee, Ni-Chung, Hwu, Wuh-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193123/
https://www.ncbi.nlm.nih.gov/pubmed/32373469
http://dx.doi.org/10.1016/j.ymgmr.2020.100591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193123/
https://www.ncbi.nlm.nih.gov/pubmed/32373469
http://dx.doi.org/10.1016/j.ymgmr.2020.100591

Ejemplares similares